Sulpitac
Sulpitac (Amisulpride 50–400 mg) — D2/D3-selective benzamide atypical for schizophrenia (negative or positive symptoms). dose-dependent dual mechanism — 50–300 mg for negative symptoms.
✓ Verificat medical de Morgan Ellis — Cercetător farmaceutic · 8 ani de experiență · Ultima recenzie: mai 2026
⚡ Răspuns rapid
Sulpitac (Amisulpride 50 / 100 / 200 / 400 mg) is a benzamide atypical antipsychotic for schizophrenia. Dose-dependent dual mechanism — low doses (50–300 mg) treat negative symptoms; higher doses (400–1200 mg) treat positive symptoms. Largely renally cleared. Available across Europe and Asia; not FDA-approved.
📦 Fiecare comandă este acoperită de politica noastră de Politica noastră de Reexpediere Garantată — dacă coletul dumneavoastră nu sosește în 20 de zile lucrătoare, îl relivrăm.
De ce să comanzi de la MedsBase
Sulpitac at MedsBase is supplied directly from a WHO-GMP certified manufacturer in plain, discreet packaging. Every order is covered by our Politica noastră de Reexpediere Garantată — perioadă de livrare de 20 de zile lucrătoare sau retrimitem fără costuri suplimentare — și se califică pentru programul nostru de loialitate pentru clienți. Livrările sunt disponibile în majoritatea destinațiilor la nivel mondial.
What Sulpitac is and how it works
Sulpitac is an amisulpride tablet supplied by Sun Pharma. Available strengths: 50 / 100 / 200 / 400 mg. Amisulpride is a benzamide atypical with selective D2/D3 antagonism — no significant action at 5-HT2A, H1, M1, or α-adrenergic receptors. The unique feature is dose-dependent action on dopamine: at low doses (50–300 mg) it preferentially blocks pre-synaptic D2 autoreceptors, increasing dopamine release in the prefrontal cortex (treats negative symptoms); at higher doses (400–1200 mg) it blocks postsynaptic D2 receptors (treats positive symptoms).
Approved across Europe and Asia for schizophrenia; not FDA-approved (oral). The intravenous formulation is FDA-approved for postoperative nausea/vomiting under a different brand name (Barhemsys) but with no oral availability in the US.
Indicații și dozaj
| Indicație | Doza inițială | Țintă | Maxim |
|---|---|---|---|
| Predominantly negative symptoms | 50 mg OD | 50–300 mg/day | 300 mg |
| Predominantly positive symptoms | 200 mg BID | 400–800 mg/day | 1200 mg |
| Mixed presentation | 200 mg BID | 400–800 mg/day | 1200 mg |
| Renal impairment (CrCl 30–60) | halve dose | — | — |
| Insuficiență renală (CrCl 10–30) | one-third normal dose | — | — |
Considerații importante de siguranță
All atypical antipsychotics carry an FDA black-box warning for increased mortality (mostly cardiovascular and infectious) when used to treat behavioural disturbance in older adults with dementia. Atypicals are not approved for dementia-related psychosis or agitation. Use in this population is off-label, last-resort, time-limited, and requires explicit risk-benefit conversation.
Amisulpride produces dose-dependent QT prolongation — meaningful at higher doses. Pre-treatment ECG advised. Avoid in known long QT, hypokalaemia/hypomagnesaemia, recent MI, uncompensated heart failure, and concurrent QT-prolonging therapy.
Amisulpride raises prolactin substantially — comparable to risperidone. Same downstream effects: amenorrhoea, galactorrhoea, sexual dysfunction, accelerated osteoporosis. Switch to aripiprazole if symptomatic.
EPS rises sharply above 800 mg/day.
Efecte secundare frecvente
- Hyperprolactinaemia and downstream effects — common.
- EPS / akathisia — dose-dependent.
- Creșterea în greutate — modest.
- Insomnia, anxiety — at low doses (presynaptic D2 stimulation).
- Prelungirea intervalului QT — dose-dependent.
Interacțiuni medicamentoase
- Alte medicamente care prelungesc intervalul QT — additive risk; avoid combination.
- Antihipertensive — additive hypotension.
- Levodopa — antagonism; avoid in Parkinson’s.
- Renally-cleared drugs — additive renal burden.
Sarcina, alăptare, pediatric
Pregnancy: limited data; weigh against untreated illness. Breastfeeding: passes into milk; usually requires monitoring. Paediatric: not licensed in most countries.
Depozitare
Păstrare la 15–30 °C în ambalajul original.
Întrebări frecvente
How does Sulpitac’s dose-dependent action work?
At low doses, amisulpride preferentially blocks presynaptic D2 autoreceptors, which actually increases dopamine release in the prefrontal cortex — useful for negative symptoms (apathy, blunting, withdrawal). At higher doses, it occupies postsynaptic D2 receptors and produces classical antipsychotic blockade for positive symptoms. The dose-response curve is unique among atypicals.
Why is Sulpitac not FDA-approved?
Amisulpride was developed by Sanofi in France and approved across Europe and much of Asia from 1986. Sanofi did not pursue FDA approval for the oral formulation. The IV formulation is FDA-approved for postoperative nausea (Barhemsys) but the oral psychiatric form is not available in the US.
Will Sulpitac affect my fertility?
Yes — amisulpride raises prolactin, with the same fertility, menstrual, sexual, and bone-density effects as risperidone. Switch to aripiprazole if hyperprolactinaemia is symptomatic.
How long until Sulpitac works?
Acute effect on agitation in days. Antipsychotic effect on positive symptoms 1–2 weeks; full effect at 4–6 weeks. Negative symptoms (low-dose use) may take weeks to months.
Will Sulpitac make me gain weight?
Modest — typically 1–3 kg over 6 months. Less than olanzapine/quetiapine.
Does Sulpitac prolong the QT interval?
Yes — meaningful at higher doses. Pre-treatment ECG is recommended. Avoid in patients with QT risk factors.
Can Sulpitac be combined with other antipsychotics?
Generally avoid — additive QT and prolactin risk. Specialist supervision required.
What about driving on Sulpitac?
Sedation is mild compared to olanzapine or quetiapine. Most patients drive normally on stable doses.
Can Sulpitac be stopped abruptly?
Taper over 2–4 weeks. Relapse risk in schizophrenia is the main concern.
Why does Sulpitac need renal dose adjustment?
Amisulpride is largely renally cleared (50–60%). Renal impairment raises levels substantially, increasing EPS, hyperprolactinaemia, and QT risk. Dose adjustment is mandatory in CrCl < 60.
Alte Medicamente pentru Sănătatea Mintală
- Aripicon (Aripiprazole — D2 partial agonist)
- Olanzap (Olanzapine — robust antipsychotic)
- Risdone (Risperidone)
- Seroquit (Quetiapine — bipolar depression)
- Atlura (Lurasidone — metabolically clean)
Mai multe opțiuni în Medicamente pentru Sănătatea Mintală și Psihiatrice
Clasificate în funcție de volumul recent de comenzi MedsBase — ce aleg alți clienți în această categorie.
| Cantitate | 30 Comprimat/e, 60 Comprimat/e, 90 Comprimat/e, 180 Comprimat/e |
|---|---|
| Stength | 50 mg, 100 mg |
Sulpitac
Întrebări și răspunsuri
Sulpitac
Produse similare
Recenzii
Nu există recenzii încă